JPRN-UMIN000007787
已完成
3 期
Randomized phase III trial of surgery followed by mFOLFOX6 as adjuvant chemotherapy versus peri-operative mFOLFOX6 plus cetuximab for KRAS wild type resectable liver metastases of colorectal cancer - EXPERT
Hepato-biliary-pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo0 个研究点目标入组 500 人2012年4月19日
概览
- 阶段
- 3 期
- 干预措施
- 未指定
- 疾病 / 适应症
- Resectable colorectal liver metastases
- 发起方
- Hepato-biliary-pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo
- 入组人数
- 500
- 状态
- 已完成
- 最后更新
- 2年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- 未提供
排除标准
- •(1\) Extrahepatic metastases or history of extrahepatic metastases (2\) Metachronous 1 liver metastasis (3\) More than 9 liver metastases (4\) Prior local therapy for liver metastases (5\) Severe comorbidity (6\) Synchronous multiple malignancy or metachronous multiple malignancy within 5 years disease free interval (7\) Severe infectious disease (8\) Women who are unwilling to avoid pregnancy. Women who are pregnant or breastfeeding . Women with a positive pregnancy test (9\) Psychological disorder (10\) Considered not appropriate for surgery
结局指标
主要结局
未指定
相似试验
尚未招募
3 期
A phase III randomized study evaluating surgery of residual disease in patients with metastatic gastro-intestinal stromal tumor responding to imatinib mesylateGastro-intestinal stromal tumour (GIST)Cancer - Other cancer typesACTRN12609000681257European Organisation for Research and Treatment of Cancer (EORTC)350
尚未招募
3 期
A phase III randomized study evaluating surgery of residual disease in patients with metastatic gastro-intestinal stromal tumor responding to Imatinib mesylate.bowel wall cancerGIST1001799010017998NL-OMON32805European Organisation for Research in Treatment of Cancer (EORTC)60
进行中（未招募）
不适用
A phase III randomized study evaluating surgery of residual disease in patients withmetastatic gastro-intestinal stromal tumor responding to Imatinib mesylate.EUCTR2007-002257-23-GBEuropean Organization for Research and Treatment of Cancer350
进行中（未招募）
1 期
A phase III randomized study evaluating surgery of residual disease in patients withmetastatic gastro-intestinal stromal tumor responding to Imatinib mesylate.Metastatic gastro-intestinal stromal tumorMedDRA version: 9.1Level: LLTClassification code 10062427Term: Gastrointestinal stromal tumorEUCTR2007-002257-23-FREuropean Organization for Research and Treatment of Cancer350
进行中（未招募）
不适用
A phase III randomized study evaluating surgery of residual disease in patients withmetastatic gastro-intestinal stromal tumor responding to Imatinib mesylate.EUCTR2007-002257-23-NLEuropean Organization for Research and Treatment of Cancer350